Eli Lilly stock slips below $1,145 support as heavy selling pressure continues

Traders Union
All News
Stocks
Eli Lilly drops 3.81% to $1,186 today

Highlights

Eli Lilly reported 48% revenue growth in Q2 2026, led by demand for Mounjaro and Zepbound and increased international sales.
The LillyDirect telehealth service began prescription delivery for Zepbound, broadening patient access to new therapies at home.
Eli Lilly stock trades with bearish momentum and short-term selling pressure, projected to consolidate between $1,145 to $1,213 with a high probability of further downside.

Obesity drug growth and institutional buying as selling pressure lingers

Eli Lilly recorded strong financial results in the second quarter of 2026, reporting 48% revenue growth fueled by its obesity drugs Mounjaro and Zepbound, as well as rapid expansion in international markets. The company also launched the LillyDirect telehealth platform, allowing Zepbound patients to receive prescription deliveries at home, according to Pharmexec, which expands access and convenience for new therapies. During the same period, Citadel significantly increased its stake in Eli Lilly to 945,000 shares with a total market value of $1.18 billion, reflecting recent institutional activity—though price action has remained under broader selling pressure.

Downside bias confirmed as momentum weakens and resistance levels hold

On the technical side, LLY/USD has slipped below the MA-20 and MA-50 on the H1 chart, while maintaining a position above the MA-200 on the daily timeframe. The Ichimoku Kijun stands at $1,225 and now acts as immediate resistance. Momentum readings are weak, with RSI at 33.1 signaling 'Sell', MACD giving a Sell signal, and ADX indicating a neutral trend. Both Stoch RSI and CCI are in oversold territory, while Bull/Bear Power confirms heavy selling pressure intraday. The Awesome Oscillator further underlines the downside bias and short-term weakness.

Downward consolidation likely as rebound prospects remain muted

Over the next several trading days, the anticipated price range for LLY is $1,145 to $1,213, representing a typical volatility band relative to current levels. The probability of a rebound is very low, with a very high likelihood of continued downside moves. Baseline expectations call for consolidation within this zone. Should a bullish reversal occur, it would require a sustained break above the $1,225 resistance; conversely, a decisive close below the $1,145 support could trigger a new wave of selling.

Viktoras Karapetjanc, expert at Traders Union, highlights the strong fundamental momentum in Eli Lilly driven by blockbuster drug sales and rapid international growth. He notes that institutional buying, notably from Citadel, signals mounting confidence despite recent price weakness and a short-term correction. The analyst sees robust revenue and platform expansion as key positives that should support a constructive medium-term outlook. "While the technical picture suggests near-term pressure, I believe Eli Lilly's fundamentals and institutional interest will draw buyers back on consolidations above $1,145."

Earlier, analysts noted that Eli Lilly's strong product pipeline and recent approvals supported a bullish scenario, though technical risks were noted. Amid the current breakdown below key moving averages and persistent selling pressure, traders should monitor the $1,145 support as a critical downside risk in the days ahead.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.